PSMA-targeted delivery of docetaxel in prostate cancer using small-sized PDA-based micellar nanovectors

被引:0
|
作者
Rosales-Barrios, Cristian [1 ]
Gonzalez-Sanchez, Zaira I. [2 ,3 ,4 ]
Zuliani, Alessio [1 ]
Jimenez-Vacas, Juan M. [5 ,6 ]
Luque, Raul M. [5 ,6 ]
Pozo, David [2 ,3 ]
Khiar, Noureddine [1 ]
机构
[1] Univ Seville, CSIC, Inst Chem Res IIQ, Asymmetr Synth & Funct Nanosyst Grp Art &Fun, C-Americo Vespucio 49, Seville 41092, Spain
[2] Univ Seville, Univ Pablo Olavide, CSIC, Dept Integrat Pathophysiol & Therapies,Andalusian, Av Americo Vespucio 24, Seville 41092, Spain
[3] Univ Seville, Dept Med Biochem Mol Biol & Immunol, Sch Med, Av Sanchez Pizjuan S-N, Seville 41009, Spain
[4] Pontificia Univ Catolica Madre & Maestra PUCMM, Nanobiol Lab, Dept Nat & Exact Sci, Hwy Duarte km 1-5, Santiago De Los Caballero 822, Dominican Rep
[5] Univ Hosp Reina Sofia HURS, Maimonides Inst Biomed Res Cordoba IMIB, Ctr Invest Biomed Red Fisiopatol Obes & Nutr CIBER, Av Menendez Pidal S-N, Cordoba 14004, Spain
[6] Univ Cordoba, Dept Cell Biol Physiol & Immunol, Campus Rabanales, Cordoba 14004, Spain
关键词
Prostate cancer; PSMA; Active targeting; Passive targeting; Stable Supramolecular Micelles; MEMBRANE ANTIGEN PSMA; POLYDIACETYLENE MICELLES; DRUG-DELIVERY; EXPRESSION; INHIBITORS; NANOPARTICLES; ACCUMULATION; RESISTANCE; DESIGN; CELLS;
D O I
10.1016/j.jconrel.2025.01.062
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
In this study, we present the first comparative analysis of active and passive drug delivery systems for docetaxel (DTX) in prostate cancer using supramolecular self-assembled micellar nanovectors. Specifically, we developed two novel micelles based on polydiacetylenic amphiphiles (PDA) for passive and active targeting. The active targeting micelles were designed with a prostate-specific membrane antigen (PSMA) ligand, ACUPA, to facilitate recognition by PSMA-positive cancer cells. These PDA-based micelles feature a well-defined structure with a hydrophobic PDA core and a surface functionalized with PEG, and for active targeting, ACUPA. Our micelles demonstrated excellent encapsulation capacity, significantly improving DTX solubility in water, a crucial factor for clinical drug use. In vitro studies confirmed the safety and cytotoxic profiles of both systems, with ACUPAfunctionalized micelles showing notable internalization into PSMA-positive LNCaP cells, mediated through the PSMA-ACUPA interaction. In vivo imaging revealed preferential accumulation of ACUPA-functionalized nanomicelles in LNCaP xenograft tumors, suggesting enhanced retention via specific ACUPA-PSMA interactions and active uptake by LNCaP cells. Notably, Balb/c-Foxn1nu/nu early in vivo studies showed a marked reduction in tumor volume and tumor expression levels of proliferation, cell cycle progression, cell survival and anti-apoptotic markers with DTX-loaded micelles functionalized with ACUPA compared to those without ACUPA. Overall, our studies collect initial evidence regarding the feasibility of supramolecular self-assembly of ACUPA-PDA-based nanomicelles for PSMA-targeted drug chemotherapy delivery developments.
引用
收藏
页码:890 / 905
页数:16
相关论文
共 50 条
  • [31] Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [F-18] DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation
    Shenderov, Eugene
    Gorin, Michael A.
    Kim, Seohyun
    Johnson, Pamela T.
    Allaf, Mohamad E.
    Partin, Alan W.
    Pomper, Martin G.
    Antonarakis, Emmanuel S.
    Pienta, Kenneth J.
    Rowe, Steven P.
    UROLOGY CASE REPORTS, 2018, 17 : 22 - 25
  • [32] PSMA-Targeted Supramolecular Nanoparticles Prepared From Cucurbit[8]uril-Based Ternary Host-Guest Recognition for Prostate Cancer Therapy
    Zhang, Xueyan
    Qi, Shaolong
    Liu, Dahai
    Du, Jianshi
    Jin, Jingji
    FRONTIERS IN CHEMISTRY, 2022, 10
  • [33] Phase 1 study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC)
    Morris, M.
    Vogelzang, N. J.
    Sartor, O.
    Armour, A.
    Groaning, M.
    Messmann, R.
    Robarts, A.
    Petrylak, D. P.
    Tolcher, A.
    Gordon, M. S.
    Babiker, H.
    ANNALS OF ONCOLOGY, 2017, 28
  • [34] DEEP LEARNING ALGORITHM IMPROVES IDENTIFICATION OF MEN WITH LOW RISK PROSTATE CANCER USING PSMA-TARGETED 99MTC-MIP-1404 SPECT/CT
    Meyer, Alexa
    Stambler, Nancy
    Sjostrand, Karl
    Richter, Jens
    Allaf, Mohamad
    Rowe, Steven
    Wong, Vivien
    Anand, Aseem
    Gorin, Michael
    JOURNAL OF UROLOGY, 2020, 203 : E1195 - E1196
  • [35] 225Ac-PSMA-617 targeted alpha therapy after Docetaxel based chemotherapy in the patients of metastatic castration resistant prostate cancer
    Sen, Ishita
    Pant, Vineet
    Thakral, Parul
    Raina, Vinod
    Das, Subha
    Sharma, Kanchan
    Manda, Divya
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [36] Phase 1 study of the PSMA-targeted small-molecule drug conjugate EC1 169 in patients with metastatic castrate-resistant prostate cancer (mCRPC).
    Morris, Michael J.
    Vogelzang, NicholasJ.
    Sartor, Oliver
    Armour, Alison
    Groaning, Michael
    Robarts, Adam
    Petrylak, Daniel Peter
    Tolcher, Anthony W.
    Gordon, Michael S.
    Babiker, Hani M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [37] Phase 1 study of the PSMA-targeted tubulysin small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC)
    Ejadi, S.
    Vogelzang, N.
    Sartor, A.
    Clark, R.
    Tolcher, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S74 - S75
  • [38] Dendritic Cell Based PSMA Immunotherapy for Prostate Cancer Using a CD40-Targeted Adenovirus Vector
    Williams, Briana Jill
    Bhatia, Shilpa
    Adams, Lisa K.
    Boling, Susan
    Carroll, Jennifer L.
    Li, Xiao-Lin
    Rogers, Donna L.
    Korokhov, Nikolay
    Kovesdi, Imre
    Pereboev, Alexander V.
    Curiel, David T.
    Mathis, J. Michael
    PLOS ONE, 2012, 7 (10):
  • [39] Phase 1 study of the PSMA-targeted tubulysin small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC).
    Morris, Michael J.
    Petrylak, Daniel Peter
    Sartor, A. Oliver
    Vogelzang, Nicholas J.
    Groaning, Michael
    Ejadi, Samuel
    Tolcher, Anthony W.
    Babiker, Hani M.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [40] Using [18F]DCFPyL in prostate cancer patient-derived xenograft (LuCaP PDX) organoids to define parameters influencing PSMA-targeted PET Imaging
    White, Margaret
    Wong, Karen
    Roy, Jyoti
    Opina, Ana Christina
    Basuli, Falguni
    Zhang, Xiang
    Woodroofe, Carolyn
    Swenson, Rolf
    Choyke, Peter
    Jagoda, Elaine
    Kelly, Kathleen
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60